SANA

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

High

5.079

Open

4.980

VWAP

Vol

4.33M

Mkt Cap

1.10B

Low

4.820

Amount

EV/EBITDA(TTM)

Total Shares

221.50M

1.01B

EV/OCF(TTM)

P/S(TTM)

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

6 Analyst Rating

100.82% Upside

Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 9.80 USD with a low forecast of 5.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

100.82% Upside

Current: 4.880

Low

5.00

Averages

9.80

High

15.00

100.82% Upside

Current: 4.880

Low

5.00

Averages

9.80

High

15.00

Morgan Stanley

Maxwell Skor

Overweight

initiated

$12

2025-07-02

Reason

Morgan Stanley

Maxwell Skor

Price Target

$12

2025-07-02

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology with an Overweight rating and $12 price target. Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company's proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$11

2025-03-18

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$11

2025-03-18

Reiterates

Strong Buy

Reason

Citizens Capital Markets

Reni Benjamin

Hold

Buy

Upgrades

2025-03-18

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

2025-03-18

Upgrades

Hold

Buy

Reason

Citizens JMP upgraded Sana Biotechnology to Outperform from Market Perform with a $5 price target. The firm cites its cash per share and platform value analysis for the upgrade. Sana reported Q4 results and provided corporate updates, including longer follow-up from the Upsala IST demonstrating three-month islet cell viability, the analyst tells investors in a research note. Citizens says that with three-month follow-up from the modified pancreatic islet cell IST program validating the Hypoimmune platform in type 1 diabetes, SC291 data in autoimmune diseases expected in 2025, and a cash position of $152.5M, Sana shares are undervalued.

Jefferies

Roger Song

Strong Buy

Initiates

2025-03-14

Reason

Jefferies

Roger Song

Price Target

2025-03-14

Initiates

Strong Buy

Reason

Jefferies analyst Roger Song initiated coverage of Sana Biotechnology with a Buy rating and $7 price target. Sana is a clinical stage biotech focused on bringing engineered cells as medicines to market by leveraging its proprietary hypo-immune editing platform, the analyst tells investors in a research note. The firm says the company has three assets in development for three different disease spaces. It models peak adjusted revenues of $2.8B.

TD Cowen

Marc Frahm

Hold

Strong Buy

Upgrades

n/a

2025-01-08

Reason

TD Cowen

Marc Frahm

Price Target

n/a

2025-01-08

Upgrades

Hold

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$8 → $11

2025-01-08

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$8 → $11

2025-01-08

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sana Biotechnology Inc (SANA.O) is -6.59, compared to its 5-year average forward P/E of -5.14. For a more detailed relative valuation and DCF analysis to assess Sana Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.14

Current PE

-6.59

Overvalued PE

-1.64

Undervalued PE

-8.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.38

Current EV/EBITDA

-5.55

Overvalued EV/EBITDA

-0.33

Undervalued EV/EBITDA

-8.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00